Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy

Timothy F. Kozelsky, Gregory E. Meyers, Jeff A Sloan, Thomas G. Shanahan, Stephen J. Dick, Randy L. Moore, George P. Engeler, Albert R. Frank, Timothy K. McKone, Rodolfo E. Urias, Miljenko V. Pilepich, Paul J. Novotny, James A. Martenson

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Purpose: A phase III, randomized, double-blind study was conducted by the North Central Cancer Treatment Group to determine the efficacy and toxicity of oral glutamine for the prevention of acute diarrhea in patients receiving pelvic radiation therapy (RT). Patients and Methods: All 129 patients enrolled from 14 institutions between February 1998 and October 1999 were eligible. Patients received 4 g of glutamine or placebo orally, twice a day, beginning with the first or second day of RT and continuing for 2 weeks after RT. During treatment, patients were assessed weekly for toxicity, and a bowel function questionnaire was administered. The primary measures of treatment efficacy were diarrhea levels measured by maximum grade of diarrhea, incidence of diarrhea, and average diarrhea score. After completion of RT, the bowel function questionnaire was administered weekly for 4 weeks and at 12 and 24 months. Toxicity was measured by National Cancer Institute common toxicity criteria. Results: The median age of patients was 69 years (range, 34 to 86 years). The two treatment arms were balanced with respect to all baseline factors. There were no significant differences in toxicity by treatment. Quality-of-life scores and the mean number of problems reported on the bowel function questionnaire were virtually identical for both treatment groups. The incidence of grade 3 or higher diarrhea was 20% for the glutamine arm and 19% for the placebo arm (P = .99). The maximum number of stools per day was 5.1 for the glutamine arm and 5.2 for the placebo arm (P = .99). Conclusion: There is no evidence of a beneficial effect of glutamine during pelvic RT.

Original languageEnglish (US)
Pages (from-to)1669-1674
Number of pages6
JournalJournal of Clinical Oncology
Volume21
Issue number9
DOIs
StatePublished - May 1 2003

Fingerprint

Glutamine
Double-Blind Method
Diarrhea
Radiotherapy
Placebos
Therapeutics
National Cancer Institute (U.S.)
Incidence
Quality of Life
Surveys and Questionnaires
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. / Kozelsky, Timothy F.; Meyers, Gregory E.; Sloan, Jeff A; Shanahan, Thomas G.; Dick, Stephen J.; Moore, Randy L.; Engeler, George P.; Frank, Albert R.; McKone, Timothy K.; Urias, Rodolfo E.; Pilepich, Miljenko V.; Novotny, Paul J.; Martenson, James A.

In: Journal of Clinical Oncology, Vol. 21, No. 9, 01.05.2003, p. 1669-1674.

Research output: Contribution to journalArticle

Kozelsky, TF, Meyers, GE, Sloan, JA, Shanahan, TG, Dick, SJ, Moore, RL, Engeler, GP, Frank, AR, McKone, TK, Urias, RE, Pilepich, MV, Novotny, PJ & Martenson, JA 2003, 'Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy', Journal of Clinical Oncology, vol. 21, no. 9, pp. 1669-1674. https://doi.org/10.1200/JCO.2003.05.060
Kozelsky, Timothy F. ; Meyers, Gregory E. ; Sloan, Jeff A ; Shanahan, Thomas G. ; Dick, Stephen J. ; Moore, Randy L. ; Engeler, George P. ; Frank, Albert R. ; McKone, Timothy K. ; Urias, Rodolfo E. ; Pilepich, Miljenko V. ; Novotny, Paul J. ; Martenson, James A. / Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 9. pp. 1669-1674.
@article{d3dcc05f2add4b228ff5e7c784244ecc,
title = "Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy",
abstract = "Purpose: A phase III, randomized, double-blind study was conducted by the North Central Cancer Treatment Group to determine the efficacy and toxicity of oral glutamine for the prevention of acute diarrhea in patients receiving pelvic radiation therapy (RT). Patients and Methods: All 129 patients enrolled from 14 institutions between February 1998 and October 1999 were eligible. Patients received 4 g of glutamine or placebo orally, twice a day, beginning with the first or second day of RT and continuing for 2 weeks after RT. During treatment, patients were assessed weekly for toxicity, and a bowel function questionnaire was administered. The primary measures of treatment efficacy were diarrhea levels measured by maximum grade of diarrhea, incidence of diarrhea, and average diarrhea score. After completion of RT, the bowel function questionnaire was administered weekly for 4 weeks and at 12 and 24 months. Toxicity was measured by National Cancer Institute common toxicity criteria. Results: The median age of patients was 69 years (range, 34 to 86 years). The two treatment arms were balanced with respect to all baseline factors. There were no significant differences in toxicity by treatment. Quality-of-life scores and the mean number of problems reported on the bowel function questionnaire were virtually identical for both treatment groups. The incidence of grade 3 or higher diarrhea was 20{\%} for the glutamine arm and 19{\%} for the placebo arm (P = .99). The maximum number of stools per day was 5.1 for the glutamine arm and 5.2 for the placebo arm (P = .99). Conclusion: There is no evidence of a beneficial effect of glutamine during pelvic RT.",
author = "Kozelsky, {Timothy F.} and Meyers, {Gregory E.} and Sloan, {Jeff A} and Shanahan, {Thomas G.} and Dick, {Stephen J.} and Moore, {Randy L.} and Engeler, {George P.} and Frank, {Albert R.} and McKone, {Timothy K.} and Urias, {Rodolfo E.} and Pilepich, {Miljenko V.} and Novotny, {Paul J.} and Martenson, {James A.}",
year = "2003",
month = "5",
day = "1",
doi = "10.1200/JCO.2003.05.060",
language = "English (US)",
volume = "21",
pages = "1669--1674",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy

AU - Kozelsky, Timothy F.

AU - Meyers, Gregory E.

AU - Sloan, Jeff A

AU - Shanahan, Thomas G.

AU - Dick, Stephen J.

AU - Moore, Randy L.

AU - Engeler, George P.

AU - Frank, Albert R.

AU - McKone, Timothy K.

AU - Urias, Rodolfo E.

AU - Pilepich, Miljenko V.

AU - Novotny, Paul J.

AU - Martenson, James A.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Purpose: A phase III, randomized, double-blind study was conducted by the North Central Cancer Treatment Group to determine the efficacy and toxicity of oral glutamine for the prevention of acute diarrhea in patients receiving pelvic radiation therapy (RT). Patients and Methods: All 129 patients enrolled from 14 institutions between February 1998 and October 1999 were eligible. Patients received 4 g of glutamine or placebo orally, twice a day, beginning with the first or second day of RT and continuing for 2 weeks after RT. During treatment, patients were assessed weekly for toxicity, and a bowel function questionnaire was administered. The primary measures of treatment efficacy were diarrhea levels measured by maximum grade of diarrhea, incidence of diarrhea, and average diarrhea score. After completion of RT, the bowel function questionnaire was administered weekly for 4 weeks and at 12 and 24 months. Toxicity was measured by National Cancer Institute common toxicity criteria. Results: The median age of patients was 69 years (range, 34 to 86 years). The two treatment arms were balanced with respect to all baseline factors. There were no significant differences in toxicity by treatment. Quality-of-life scores and the mean number of problems reported on the bowel function questionnaire were virtually identical for both treatment groups. The incidence of grade 3 or higher diarrhea was 20% for the glutamine arm and 19% for the placebo arm (P = .99). The maximum number of stools per day was 5.1 for the glutamine arm and 5.2 for the placebo arm (P = .99). Conclusion: There is no evidence of a beneficial effect of glutamine during pelvic RT.

AB - Purpose: A phase III, randomized, double-blind study was conducted by the North Central Cancer Treatment Group to determine the efficacy and toxicity of oral glutamine for the prevention of acute diarrhea in patients receiving pelvic radiation therapy (RT). Patients and Methods: All 129 patients enrolled from 14 institutions between February 1998 and October 1999 were eligible. Patients received 4 g of glutamine or placebo orally, twice a day, beginning with the first or second day of RT and continuing for 2 weeks after RT. During treatment, patients were assessed weekly for toxicity, and a bowel function questionnaire was administered. The primary measures of treatment efficacy were diarrhea levels measured by maximum grade of diarrhea, incidence of diarrhea, and average diarrhea score. After completion of RT, the bowel function questionnaire was administered weekly for 4 weeks and at 12 and 24 months. Toxicity was measured by National Cancer Institute common toxicity criteria. Results: The median age of patients was 69 years (range, 34 to 86 years). The two treatment arms were balanced with respect to all baseline factors. There were no significant differences in toxicity by treatment. Quality-of-life scores and the mean number of problems reported on the bowel function questionnaire were virtually identical for both treatment groups. The incidence of grade 3 or higher diarrhea was 20% for the glutamine arm and 19% for the placebo arm (P = .99). The maximum number of stools per day was 5.1 for the glutamine arm and 5.2 for the placebo arm (P = .99). Conclusion: There is no evidence of a beneficial effect of glutamine during pelvic RT.

UR - http://www.scopus.com/inward/record.url?scp=0038474021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038474021&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.05.060

DO - 10.1200/JCO.2003.05.060

M3 - Article

C2 - 12721240

AN - SCOPUS:0038474021

VL - 21

SP - 1669

EP - 1674

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -